Albumin reduces thrombogenic potential of single-walled carbon nanotubes

Вахрушева, Т. В.; Gusev, А. А.; Гусев, С. А.; Vlasova, Irina I.

doi:10.1016/j.toxlet.2013.05.642

Cited by 24 publications

(9 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These coatings have also been used to decrease interference with platelets and coagulation factors. PEGylated SWCNTs caused less platelet aggregation than uncoated carboxylated particles, which is consistent with the idea that prevention of protein binding decreases interference with hemostasis [89, 90]. Coating with PEG, however, was not successful for all materials.…”

Section: How To Prevent Adverse Effects On Hemostasissupporting

confidence: 77%

“…Coating with PEG, however, was not successful for all materials. No effect of PEGylation was observed for Au particles and SWCNTs [52, 90, 131]. The relative inefficacy of PEGylation for SWCNTs was also seen in studies on complement activation and suggests that obtaining a sufficient coating of these particles may be difficult [132, 133].…”

Section: How To Prevent Adverse Effects On Hemostasismentioning

confidence: 99%

See 1 more Smart Citation

Action of Nanoparticles on Platelet Activation and Plasmatic Coagulation

Frőhlich

2016

CMC

View full text Add to dashboard Cite

Nanomaterials can get into the blood circulation after injection or by release from implants but also by permeation of the epithelium after oral, respiratory or dermal exposure. Once in the blood, they can affect hemostasis, which is usually not intended. This review addresses effects of biological particles and engineered nanomaterials on hemostasis. The role of platelets and coagulation in normal clotting and the interaction with the immune system are described. Methods to identify effects of nanomaterials on clotting and results from in vitro and in vivo studies are summarized and the role of particle size and surface properties discussed. The literature overview showed that mainly pro-coagulative effects of nanomaterials have been described. In vitro studies suggested stronger effects of smaller than of larger NPs on coagulation and a greater importance of material than of surface charge. For instance, carbon nanotubes, polystyrene particles, and dendrimers inferred with clotting independent from their surface charge. Coating of particles with polyethylene glycol was able to prevent interaction with clotting by some particles, while it had no effect on others and the more recently developed bio-inspired surfaces might help to design coatings for more biocompatible particles. The mainly pro-coagulative action of nanoparticles could present a particular risk for individuals affected by common diseases such as diabetes, cancer, and cardiovascular diseases. Under standardized conditions, in vitro assays using human blood appear to be a suitable tool to study mechanisms of interference with hemostasis and to optimize hemocompatibility of nanomaterials.

show abstract

Section: How To Prevent Adverse Effects On Hemostasissupporting

confidence: 77%

Section: How To Prevent Adverse Effects On Hemostasismentioning

confidence: 99%

Action of Nanoparticles on Platelet Activation and Plasmatic Coagulation

Frőhlich

2016

CMC

View full text Add to dashboard Cite

show abstract

“…The structural analysis of HSA complexes can guide us in the rational design of this protein by changing its drug binding ability using several strategies including, the modification of compounds’ structure, or the regulation of drugs to each other, or edit certain HSA amino acids rendering the HSA carrier more effective for drug delivery to the target site [96]. No doubt, HSA will be more extensively studied in various fields except that it will be more application in medicine field owing to its fascinating properties [95,111–119]. …”

Section: Discussionmentioning

confidence: 99%

Interactive Association of Drugs Binding to Human Serum Albumin

Yang

Zhang

Liang

2014

IJMS

280

202

View full text Add to dashboard Cite

Human serum albumin (HSA) is an abundant plasma protein, which attracts great interest in the pharmaceutical industry since it can bind a remarkable variety of drugs impacting their delivery and efficacy and ultimately altering the drug’s pharmacokinetic and pharmacodynamic properties. Additionally, HSA is widely used in clinical settings as a drug delivery system due to its potential for improving targeting while decreasing the side effects of drugs. It is thus of great importance from the viewpoint of pharmaceutical sciences to clarify the structure, function, and properties of HSA–drug complexes. This review will succinctly outline the properties of binding site of drugs in IIA subdomain within the structure of HSA. We will also give an overview on the binding characterization of interactive association of drugs to human serum albumin that may potentially lead to significant clinical applications.

show abstract

“…The zeta potentials of our samples are in the range of À10 mV (Table 1) suggesting that the surface all of our SWCNT samples are covered but with unknown amount of HSA. Vakhrusheva and her coworkers (Vakhrusheva et al, 2013), showed that PEG-SWCNTs adsorb much less (0.5 w/w) HSA than the carboxylated ones (>2.4 w/w). This feature of PEG-SWCNTs might be the reason of their extremely high platelet activation ability.…”

Section: Discussionmentioning

confidence: 96%

“…Vakhrusheva and her coworkers (Vakhrusheva et al, 2013) claimed that HSA has protective effect against platelet activation of SWCNTs. The zeta potential of HSA in phosphate buffer between pH 6.4-8.4 is between À7 and À14 mV (Tousi et al, 2011).…”

Section: Discussionmentioning

confidence: 99%